Aims Sacubitril/valsartan improves morbidity and mortality in patients with heart failure and
reduced ejection fraction (HFrEF). Whether initiation of sacubitril/valsartan limits the use and …

Aims In this analysis, we utilized data from PARADIGM‐HF to test the hypothesis that
participants who exhibited any dose reduction during the trial would have similar benefits …

Purpose PARADIGM-HF demonstrated the superiority of sacubitril/valsartan over enalapril in
patients with heart failure and reduced ejection fraction (HF-REF). How widely applicable …

Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart
failure with reduced ejection fraction (HFrEF). However, the effectiveness of …

Background Sacubitril/valsartan significantly reduced heart failure hospitalization and
mortality in PARADIGM‐HF (Prospective Comparison of Angiotensin Receptor‐Neprilysin …

Current guidelines recommend angiotensin receptor blocker neprilysin inhibitors
(ARNI)(sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor …

Aims To compare baseline characteristics of patients with heart failure with reduced ejection
fraction (HFrEF) initiated on sacubitril/valsartan compared with patients continued on …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

Background Sacubitril/valsartan is an effective treatment for heart failure with reduced
ejection fraction (HFrEF) based on clinical trial data. However, little is known about its use or …

Aims Practice guidelines recommend sacubitril/valsartan for heart failure with reduced
ejection fraction. The aim of our study was to describe the use of sacubitril/valsartan in real …